DOP31 Serum protein markers for early and differential IBD diagnosis validated by machine learning approaches
S. Verstockt1,2, N. Verplaetse2,3, D. Raimondi3, B. Verstockt1,4, E. Glorieus5, M. De Decker6, L. Hannes2, V. Ballet4, E. Vandeput1, Y. Moreau3, M. Ferrante1,4, D. Laukens5, F. Mana6, M. De Vos5, S. Vermeire1,4, I. Cleynen2
1Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium, 2Laboratory for Complex Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium, 3Department of Electrical Engineering ESAT, KU Leuven, Leuven, Belgium, 4Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium, 5Department of Gastroenterology, University Hospital of Ghent, Ghent, Belgium, 6Department of Gastroenterology, University Hospitals Brussels, Brussels, Belgium
The inflammatory bowel diseases (IBD), Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory conditions with a polygenic and multifactorial pathogenesis. Intensified treatment early in the disease course of IBD results in better outcomes. This is, however, challenged by the diagnostic delay faced in IBD, and especially in CD. Therefore, markers supporting early and differential diagnosis are needed. In this study, we aimed to discriminate IBD patients from non-IBD controls, and CD from UC patients, using serum protein profiles combined with an IBD polygenic risk score.
Patients naïve for immunosuppressives and biologicals, and without previous IBD-related surgery were prospectively included within 3 months after diagnosis, across three Belgian IBD referral centres (PANTHER study). We collected serum from 127 patients (88 CD, 39 UC) and 66 age- and gender-matched non-IBD controls. Relative serum levels of 576 unique proteins were quantified (OLINK). Proteins were ranked according to (1) adjusted (adj.)
Following statistical analysis, 243 serum proteins were found to be differentially expressed (adj.
Machine learning approaches validated top differentially expressed serum proteins with diagnostic potential in IBD. We identified a three-marker panel classifying IBD patients and non-IBD controls, and a two-marker panel discriminating UC from CD.